Papel de los anti-pd1 en el abordaje de un paciente diagnosticado con melanoma

8 / 40

4-Year Survival and Outcomes After Cessation of Pembrolizumab After <br />2 Years in Patients With Ipilimumab-Naive Advanced Melanoma in KEYNOTE-006<br />
Presented By Georgina Long at 2018 ASCO Annual Meeting